This book highlights and examines the transition of nanoparticulate drug delivery systems, operating at scales of billionths of a metre, from laboratory into a commercially viable sector. This has been a challenging journey, beginning in 2005 with the introduction of Abraxane, the first nanotechnology-based drug delivery product for the treatment of breast cancer, which marked the advent of nanotechnology in the pharmaceutical and healthcare industry. The book describes the need for various types of nanoparticulate drug delivery systems in different application areas, and assesses the challenges associated with their advance to society.